

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>25142-0002001</b>	Application No. <b>10/797,903</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Yamamoto et al.</b>	
		Filing Date <b>March 10, 2004</b>	Group Art Unit <b>1628</b>

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/A.P./	1	2003/087907	05/2003	Kubo et al.			
	2	2003/215523	11/2003	Ozawa et al.			
	3	2004/009965	01/2004	Collins et al.			
	4	2004/034026	02/2004	Wood et al.			
	5	2004/053908	03/2004	Funahashi et al.			
	6	2004/132727	07/2004	Sakai et al.			
	7	2004/152759	08/2004	Abrams et al.			
	8	2004/191254	09/2004	Fagin			
	9	2004/253205	12/2004	Yamamoto et al.			
	10	2005/014727	01/2005	Muller et al.			
	11	2005/049264	03/2005	Miwa et al.			
	12	2005/119303	06/2005	Wakabayashi et al.			
	13	2005/176802	08/2005	Tang et al.			
	14	2005/272688	12/2005	Higgins et al.			
	15	2005/277652	12/2005	Matsushima et al.			
	16	2006/004017	01/2006	Stokes et al.			
	17	2006/004029	01/2006	Tsuruok et al.			
	18	2006/079494	04/2006	Santi et al.			
	19	2006/135486	01/2006	Owa et al.			
	20	2007/004773	01/2007	Sakaguchi et al.			
	21	2007/037849	02/2007	Naito et al.			
	22	2007/078159	04/2007	Matsushima			
	23	2008/214604	09/2008	Furitsu et al.			
	24	2009/047278	02/2009	Owa et al.			
	25	2009/047365	02/2009	Owa et al.			
	26	4526988	07/1985	Hertel et al.			
/A.P./	27	5180818	01/1993	Cech et al.			

Examiner Signature <b>/Anna Pagonakis/</b>	Date Considered <b>02/23/2011</b>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>25142-0002001</b>	Application No. <b>10/797,903</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant <b>Yamamoto et al.</b>	
		Filing Date <b>March 10, 2004</b>	Group Art Unit <b>1628</b>

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/A.P./	28	5464826	11/1995	Grindey et al.			
	29	5733913	03/1998	Blankley et al.			
	30	5747651	05/1998	Lemischka			
	31	5770599	01/1998	Gibson			
	32	5792783	08/1998	Tang et al.			
	33	5891996	04/1999	Mateo de Acosta del Rio et al.			
	34	6143764	11/2000	Kubo et al.			
	35	6217866	04/2001	Schlessinger et al.			
	36	6346398	02/2002	Pavco et al.			
	37	6476040	11/2002	Norris et al.			
	38	6524583	02/2003	Thorpe et al.			
	39	6676941	01/2004	Thorpe et al.			
	40	6811779	11/2004	Rockwell et al.			
/A.P./	41	7253286	08/2007	Funahashi et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/A.P./	42	EP 1415987	05/06/2004	EP				
	43	EP 1604665	12/14/2005	EP				
	44	EP 1698623	09/06/2006	EP				
	45	EP 1859797	11/28/2007	EP				
	46	EP 1925676	05/28/2008	EP				
	47	EP 1925941	05/28/2008	EP				
	48	EP 1949902	07/30/2008	EP				
	49	EP 1964837	09/03/2008	EP				
	50	EP 203126	06/05/1986	EP				
/A.P./	51	3040486	03/03/2000	JP				

Examiner Signature <b>/Anna Pagonakis/</b>	Date Considered <b>02/23/2011</b>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>25142-0002001</b>	Application No. <b>10/797,903</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Yamamoto et al.</b>	
		Filing Date <b>March 10, 2004</b>	Group Art Unit <b>1628</b>

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/A.P./	52	3088018	07/14/2000	JP				
	53	3420549	04/18/2003	JP				
	54	2002-114710	04/16/2002	JP				
	55	2002-536414	10/29/2002	JP				
	56	2003-012668	01/15/2003	JP				
	57	2003-525595	09/02/2003	JP				
	58	2004-513964	05/13/2004	JP				
	59	2004-531549	10/14/2004	JP				
	60	2005-504111	02/10/2005	JP				
	61	2005-520834	07/14/2005	JP				
	62	2006-508981	03/16/2006	JP				
	63	11-322596	11/24/1999	JP				
	64	02-291295	12/03/1990	JP				
	65	1986/03222	06/05/1986	WIPO				
	66	1996/030347	10/3/1996	WIPO				
	67	1996/033980	10/31/1996	WIPO				
	68	1997/017329	05/15/1997	WIPO				
	69	1997/048693	12/24/1997	WIPO				
	70	1998/014437	04/09/1998	WIPO				
	71	1998/035958	08/20/1998	WIPO				
	72	1999/035146	07/15/1999	WIPO				
	73	1999/062890	12/09/1999	WIPO				
	74	2000/031048	06/02/2000	WIPO				
	75	2000/042012	07/20/2000	WIPO				
	76	2000/043366	07/27/2000	WIPO				
	77	2000/047212	08/17/2000	WIPO				
/A.P./	78	2001/002369	01/11/2001	WIPO				

Examiner Signature <b>/Anna Pagonakis/</b>	Date Considered <b>02/23/2011</b>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25142-0002001	Application No. 10/797,903
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Yamamoto et al.	
		Filing Date March 10, 2004	Group Art Unit 1628

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/A.P./	79	2001/023375	04/05/2001	WIPO				
	80	2001/027081	04/19/2001	WIPO				
	81	2001/032926	05/10/2001	WIPO				
	82	2001/040217	06/07/2001	WIPO				
	83	2001/047890	07/05/2001	WIPO				
	84	2001/060814	08/23/2001	WIPO				
	85	2002/032872	04/25/2002	WIPO				
	86	2002/036117	05/10/2002	WIPO				
	87	2002/041882	05/30/2002	WIPO				
	88	2002/072578	09/19/2002	WIPO				
	89	2002/080975	10/17/2002	WIPO				
	90	2002/088110	11/07/2002	WIPO				
	91	2002/092091	11/21/2002	WIPO				
	92	2003/006462	01/23/2003	WIPO				
	93	2003/027102	04/03/2003	WIPO				
	94	2003/028711	04/10/2003	WIPO				
	95	2003/033472	04/24/2003	WIPO				
	96	2003/050090	06/19/2003	WIPO				
	97	2003/074045	09/12/2003	WIPO				
	98	2003/079020	09/25/2003	WIPO				
	99	2004/006862	01/22/2004	WIPO				
	100	2004/020434	03/11/2004	WIPO				
	101	2004/032872	04/22/2004	WIPO				
	102	2004/032937	04/24/2004	WIPO				
	103	2004/041308	05/21/2004	WIPO				
	104	2004/043472	05/27/2004	WIPO				
/A.P./	105	2004/078144	09/16/2004	WIPO				

Examiner Signature  /Anna Pagonakis/	Date Considered  02/23/2011
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>25142-0002001</b>	Application No. <b>10/797,903</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant <b>Yamamoto et al.</b>	
		Filing Date <b>March 10, 2004</b>	Group Art Unit <b>1628</b>

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/A.P./	106	2004/080462	09/23/2004	WIPO				
	107	2004/101526	11/25/2004	WIPO				
	108	2005/027972	03/31/2005	WIPO				
	109	2005/044788	05/19/2005	WIPO				
	110	2005/051366	06/09/2005	WIPO				
	111	2005/056764	06/23/2005	WIPO				
	112	2005/063713	07/14/2005	WIPO				
	113	2005/082854	09/09/2005	WIPO				
	114	2005/092896	10/06/2005	WIPO				
	115	2005/117887	12/15/2005	WIPO				
	116	2006/030826	03/23/2006	WIPO				
	117	2006/030941	03/23/2006	WIPO				
	118	2006/030947	03/23/2006	WIPO				
	119	2006/036941	12/15/2006	WIPO				
	120	2006/062984	06/15/2006	WIPO				
	121	2006/090930	08/31/2006	WIPO				
	122	2006/090931	08/31/2006	WIPO				
	123	2006/137474	12/28/2006	WIPO				
	124	2007/015569	02/08/2007	WIPO				
	125	2007/015578	02/08/2007	WIPO				
	126	2007/040565	04/12/2007	WIPO				
	127	2007/052849	05/10/2007	WIPO				
	128	2007/052850	205/10/007	WIPO				
	129	2007/061127	05/31/2007	WIPO				
	130	2007/061130	05/31/2007	WIPO				
/A.P./	131	2007/136103	11/29/2007	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)	
Examiner Signature  /Anna Pagonakis/	Date Considered  02/23/2011
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>25142-0002001</b>	Application No. <b>10/797,903</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Yamamoto et al.</b>	
		Filing Date <b>March 10, 2004</b>	Group Art Unit <b>1628</b>

Examiner Initial	Desig. ID	Document
/A.P./	132	[Retreived from] <a href="http://www.lungcancer.org/reading/types/php">www.lungcancer.org/reading/types/php</a> , "CancerCare, Types of Lung Cancer" (2009)
	133	Agarwal et al., "Binding of Discoidin Domain Receptor 2 to Collagen I: An Atomic Force Microscopy Investigation", Biochemistry 41:11091-11098 (2002)
	134	Alvares et al., "A Novel Germ-Line Point Mutation in RET Exon 8 (Gly <sup>533</sup> Cys) in a Large Kindred with Familial Medullary Thyroid Carcinoma" The Journal of Clinical Endocrinology & Metabolism 88(11):5438-5443 (2003)
	135	Asuno-Shinyaku, "The New Drugs of Tomorrow", Update Summary 2006 December with English translation (14 pages)
	136	Baker et al., "Blockade of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling for Therapy of Metastatic Human Pancreatic Cancer", CANCER RESEARCH 62: 1996-2003 (2002)
	137	Benjamin et al., "Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal", The J. of Clin. Invest. 103(2):159-165 (1999)
	138	Bergers et al., "Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors", The Journal of Clinical Investigation 111(9):1287-1295 (2003)
	139	Bruns et al., "EFFECT OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 ANTIBODY DC101 PLUS GEMCITABINE ON GROWTH, METASTASIS AND ANGIOGENESIS OF HUMAN PANCREATIC CANCER GROWING ORTHOTOPICALLY IN NUDE MICE", Int. J. Cancer 102:101-108 (2002)
	140	Capellen et al., "Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas", Nature Genetics, 23:18-20 (1999)
	141	Carlomagno et al., "ZD6474, an Orally Available Inhibitor of KDR Tyrosine Kinase Activity, Efficiently Block Oncogenic RET Kinases", Cancer Research 62:7284-7290(2002)
	142	Carlomagno et al., "BAY 43-9006 Inhibition of Oncogenic RET Mutants", Journal of the National Cancer Institute 98(5):326-334 (2006)
	143	Chen et al., "FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies", Oncogene 24:8259-8267 (2005)
	144	Chesi et al., "Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma", Neoplasia, Blood, 97(3):729-736 (2001)
	145	Chesi et al., "Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor", Nature Genetics, 16:260-264 (1997)
	146	Elisei et al., "Identification of a Novel Point Mutation in the RET Gene (Ala883Thr), Which Is Associated with Medullary Thyroid Carcinoma Phenotype Only in Homozygous Condition", The Journal of Clinical Endocrinology & Metabolism 89(11):5823-5827 (2004)
	147	Erber et al., "Combined inhibition of VEGF- and PDGF-signaling enforces tumor vessel regression by interfering with pericytemediated endothelial cell survival mechanisms", The FASEB Journal published online 12/4/2003 (25 pages)
↓	148	Experimental And Molecular Therapeutics 30, Proceedings of the American Association for Cancer Research, Vol. 47 (2006)
/A.P./	149	Gatzemeier et al., "Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non-Small-Cell Lung Cancer", Journal of Clinical Oncology 18(19):3390-3399 (2000)

Examiner Signature <b>/Anna Pagonakis/</b>	Date Considered <b>02/23/2011</b>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>25142-0002001</b>	Application No. <b>10/797,903</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant <b>Yamamoto et al.</b>	
		Filing Date <b>March 10, 2004</b>	Group Art Unit <b>1628</b>
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/A.P./	150	Giles, F., "The Vascular Endothelial Growth Factor (VEGF) Signaling Pathway: A Therapeutic Target in Patients with Hematologic Malignancies", <i>The Oncologists</i> 6(suppl5):32-39 (2001)
	151	Haller, D., "CHEMOTHERAPY FOR ADVANCED PANCREATIC CANCER", <i>Int. J. Radiation Oncology Biol. Phys.</i> , 56(4): Supplement, pp. 16-23 (2003)
	152	Hattori et al., "Immunohistochemical Detection of K-sam Protein in Stomach Cancer", <i>Clinical Cancer Research</i> , 2:1373-1381 (1996)
	153	Haymo et al., "Pericytes in experimental MDA-MB231 tumor angiogenesis", <i>Histochemistry and Cell Biology</i> , 117(6):527-534 (2002)
	154	Heinrich et al., "Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor", <i>Hematopoiesis</i> , <i>Blood</i> 96(3):925-932 (2000)
	155	Heinrich et al., "Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies", <i>Journal of Oncology</i> 20(6):1692-1703 (2002)
	156	Hurwitz et al., "Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer", <i>The New England Journal of Medicine</i> , 350(23):2335-2342 (2004)
	157	Inai et al., "Inhibition of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane Ghosts", <i>American J. of Pathol.</i> 165(1): 35-52 (2004)
	158	Inoue et al., "MOLECULAR TARGET THERAPY TARGETING ANGIOGENESIS PATHWAYS", <i>The Nishinihon J. Urol.</i> , 66:425-432 (2004)
	159	Itoh et al., "Preferential Alternative Splicing in Cancer Generates a K-sam Messenger RNA with Higher Transforming Activity", <i>CANCER RESEARCH</i> 54: 3237-3241(1994)
	160	Jhiang, S., "The RET proto-oncogene in human cancers", <i>Oncogene</i> 19:5590-5597 (2000)
	161	Jimenez et al., "Pheochromocytoma and Medullary Thyroid Carcinoma: A New Genotype-Phenotype Correlation of the <i>RET</i> Protooncogene 891 Germline Mutation", <i>The Journal of Clinical Endocrinology &amp; Metabolism</i> 89(8):4142-4145 (2004)
	162	Johnson et al., "Paclitaxel Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Phase II Trial", <i>Journal of Clinical Oncology</i> 14(7):2054-2060 (1996)
	163	<i>JP Journal of Cancer and Chemotherapy</i> , 21(14): 2398-2406 (1994)
	164	<i>JP Journal of Cancer and Chemotherapy</i> , 31(7):1093-1095 (2004)
	165	Jung et al., "Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model", <i>European Journal of Cancer</i> , 38:1133-1140 (2002)
	166	Kashuk et al., "Phenotype-genotype correlation in Hirschsprung disease is illuminated by comparative analysis of the RET protein sequence", <i>PNAS</i> 102(25):8949-8954 (2005)
	167	Kelly et al., "Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non-Small-Cell Lung Cancer: A Southwest Oncology Group Trial", <i>Journal of Clinical Oncology</i> 19(13):3210-3218 (2001)
/A.P./	168	Kim et al., "A Phase II Study of Irinotecan Plus Cisplatin for Patients With Advanced Stage IIIB or IV NSCLC Previously Treated With Nonplatinum-Based Chemotherapy", <i>Cancer</i> , 107(4):799-805 (2006)

Examiner Signature	/Anna Pagonakis/	Date Considered	02/23/2011
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25142-0002001	Application No. 10/797,903
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Yamamoto et al.	
		Filing Date March 10, 2004	Group Art Unit 1628
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/A.P./	169	Kim et al., "An Orally Administered Multitarget Tyrosine Kinase Inhibitor, SU11248, Is a Novel Potent Inhibitor of Thyroid Oncogenic RET/Papillary Thyroid Cancer Kinases", The Journal of Clinical Endocrinology & Metabolism 91(10):4070-4075 (2006)
	170	Lesueur et al., "Polymorphisms in RET and Its Coreceptors and Ligands as Genetic Modifiers of Multiple Endocrine Neoplasia Type 2A", Cancer Research 66(2):1177-1180 (2006)
	171	Lin et al., "The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584 Inhibits Growth and Migration of Multiple Myeloma Cells in the Bone Marrow Microenvironment", Cancer Research, 62:5019-5026 (2002)
	172	Logie et al., "Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans", Human Molecular Genetics, 14(9):1153-1160 (2005)
	173	Matsui et al., "146 E7080, a novel multi-targeted tyrosine kinase inhibitor, exhibits anti-angiogenic activity via inhibition of KIT signaling in a small cell lung cancer xenograft model", European Journal of Cancer, Supplement Pergamon, Oxford, GB XP004639590 abstract
	174	McCarty et al., "ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer", Molecular Cancer Therapeutics, 3(9):1041-1048 (2004)
	175	McCulloch et al., "Astragalus-Based Chinese Herbs and Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Meta-Analysis of Randomized Trials", Journal of Clinical Oncology 24(3):419-430 (2006)
	176	Miller et al., "Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer", The New England Journal of Medicine, 357(26):2666-76 (2007)
	177	Mologni et al., "Inhibition of RET tyrosine kinase by SU5416", Journal of Mol. Endo., 37:199-212 (2006)
	178	Morgan et al., "Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies", Journal of Oncology 21(21):3955-3964 (2003)
	179	Morikawa et al., "Angiogenesis and Pericytes, Putative Positive Function of Pericytes in Angiogenesis, Course of Cellular Biology, with English translation, Cell, 37(4):164-168 (2005)
	180	Naski et al., "Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia", Nature Genetics 13:233-237 (1996)
	181	Ohe et al., "Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan", Annals of Oncology 18:317-323 (2007)
	182	Olaso et al., "DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells", The Journal of Clinical Investigation, 108(9):1369-1378 (2001)
	183	Ozols et al., "Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study", Journal of Oncology 21(17):3194-3200 (2003)
	184	Paterson et al., "Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma", Blackwell Publishing Ltd, British Journal of Haematology, 124: 595-603 (2004)
/A.P./	185	Plowright et al., "Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis" Neoplasia, Blood, 95(3): 992-998 (2000)
Examiner Signature /Anna Pagonakis/		Date Considered 02/23/2011
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25142-0002001	Application No. 10/797,903
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Yamamoto et al.	
		Filing Date March 10, 2004	Group Art Unit 1628
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/A.P./	186	Salmon et al., "Anti-Angiogenic Treatment of Gastrointestinal Malignancies", New Drugs, Cancer Investigation 23:712-726 (2005)
	187	Sandler et al., "Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer", Journal of Clinical Oncology 18(1):122-130 (2000)
	188	Santoro et al., "Drug Insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer", Nature Clinical Practice Endocrinology & Metabolism 2(1):42-52 (2006)
	189	Santoro et al., "Minireview: RET: Normal and Abnormal Functions", Endocrinology 145(12):5448-5451 (2004)
	190	Shiang et al., "Mutations in the Transmembrane Domain of FGFR3 Cause the Most Common Genetic Form of Dwarfism, Achondroplasia", Cell 78:335-342 (1994)
	191	Shimizu et al., "Orally active anti-proliferation agents: novel diphenylamine derivatives as FGF-R2 autophosphorylation inhibitors", Bioorganic & Medicinal Chem. Letters 14:875-879 (2004)
	192	Tan et al., "Randomized study of vinorelbine-gemcitabine versus vinorelbine-carboplatin in patients with advanced non-small cell lung cancer", Lung Cancer, 49:233-240 (2005)
	193	Trudel et al., "Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma", Neoplasia, Blood, 103(9): 3521-3528 (2004)
	194	Trudel et al., "CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma", Neoplasia, Blood 105(7):2941-2948 (2005)
	195	Ueda et al., "Deletion of the Carboxyl-Terminal Exons of K-sam/FGFR2 by Short Homology-mediated Recombination, Generating Preferential Expression of Specific Messenger RNAs", Cancer Research, 59:6080-6086 (1999)
	196	Van Oers et al., "A Simple and Fast Method for the Simultaneous Detection of Nine Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer and Voided Urine", Clin Cancer Res 11(21):7743-7748 (2005)
	197	Vogel et al., "Sensing extracellular matrix: An update on discoidin domain receptor function", Cellular Signalling 18:1108-1116 (2006)
	198	Wang et al., "Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer", Cancer Chemother Pharmacol, 60:601-607 (2007)
	199	Werner et al., "Gastric adenocarcinoma: pathomorphology and molecular pathology", J. Cancer Res. Clin. Oncol. 127:207-216 (2001)
	200	Willett et al., "Direct evidence that the VEGF-specific antibody bevacizumab has antivasculature effects in human rectal cancer", Nature Medicine 10(2):145-147 (2004)
	201	Wozniak et al., "Randomized Trial Comparing Cisplatin With Cisplatin Plus Vinorelbine in the Treatment of Advanced Non-Small-Cell Lung Cancer: A Southwest Oncology Group Study", Journal of Clinical Oncology 16(7):2459-2465 (1998)
	202	Yamada et al., "New Technique for Staining", Monthly Medical Technology, (1999), (13 pgs)
	203	Yanagihara et al., "Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer", Cancer Sci, 96(6):323-332 (2005)
	204	Zhu et al., "Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma", Mol Cancer Ther 4(5):787-798 (2005)
/A.P./	205	Zieger et al., "Role of Activating Fibroblast Growth Factor Receptor 3 Mutations in the Development of Bladder Tumors", Clin Cancer Res 11(21):7709-7719 (2005)

Examiner Signature /Anna Pagonakis/	Date Considered 02/23/2011
--	-------------------------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>25142-0002001</b>	Application No. <b>10/797,903</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Yamamoto et al.</b>	
		Filing Date <b>March 10, 2004</b>	Group Art Unit <b>1628</b>

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/A.P./	206	Office Action dated October 30, 2009 for European Application No.04719054.1, (5 pgs)
	207	Office Action dated August 20, 2009 for US Application No. 10/797,903, (10 pgs)
	208	European Search Report dated May 7, 2010 for European Application No. 07743994, (9pgs)
	209	European Search Report dated July 23, 2010 for European Application No. 06782407, (8 pgs)
	210	International Search report dated September 5, 2006 for International Application No. PCT/JP2006/315563, (2 pgs)
	211	International Search report dated November 17, 2006 for International Application No. PCT/JP2006/315698, (5 pgs)
	212	International Search report dated January 23, 2007 for International Application No. PCT/JP2006/322514, (10 pgs)
	213	International Search report dated January 23, 2007 for International Application No. PCT/JP2006/323881, (6 pgs)
	214	International Search report dated September 11, 2007 for International Application No. PCT/JP2007/060560, (6 pgs)
	215	International Search report dated September 4, 2007 for International Application No. PCT/JP2007/063525, (7 pgs)
	216	International Search report and Written Opinion dated September 14, 2010 for International Application No. PCT/JP2010/063804, (10 pgs)
	217	International Search report dated November 20, 2007 for International Application No. PCT/JP2007/067088, (6 pgs)
	218	International Search report dated April 1, 2008 for International Application No. PCT/JP2008/051024, (6 pgs)
	219	International Search report dated May 4, 2008 for International Application No. PCT/JP2008/051697, (7 pgs)
	220	International Search report dated January 20, 2009 for International Application No. PCT/JP2008/070321, (8 pgs)
/A.P./	221	International Search report dated March 24, 2009 for International Application No. PCT/JP2009/051244, (6 pgs)

Examiner Signature <b>/Anna Pagonakis/</b>	Date Considered <b>02/23/2011</b>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	